Comparison of patients who died within 1 year versus those surviving greater than 1 year
| . | Dead 3–12 months (N = 36) . | Survived >1 year (N = 202) . | P-value . |
|---|---|---|---|
| Median age [in years, (IQR)] | 62 (57–69) | 62 (55–68) | 0.659 |
| Performance status | |||
| 0 | 18 (11%) | 147 (89%) | 0.006 |
| 1, 2 | 18 (25%) | 55 (75%) | |
| Tumour differentiation | |||
| Low to moderate | 9 (8%) | 111 (92%) | 0.001 |
| Poor/high grade | 27 (23%) | 91 (77%) | |
| Clinical T classification | |||
| Tx, T1 or T2 | 3 (8%) | 36 (92%) | 0.142 |
| T3 or T4 | 33 (17%) | 161 (83%) | |
| Induction | |||
| Chemo | 34 (18%) | 154 (82%) | 0.013 |
| Chemo-RT | 2 (4%) | 48 (96%) | |
| Clinical response | |||
| Minimal/stable/progression | 12 (24%) | 38 (76%) | 0.012 |
| Partial/complete | 11 (9%) | 106 (91%) | |
| Missing or no data | N = 13 | N = 58 | |
| ‘R’ status | |||
| R0 | 30 (13%) | 193 (87%) | 0.014 |
| R1 | 6 (40%) | 9 (60%) | |
| Path stage | |||
| 0 (CPR) | 0 (0%) | 28 (100%) | 0.001 |
| I | 2 (7%) | 26 (93%) | |
| II | 5 (8%) | 56 (92%) | |
| III | 27 (23%) | 90 (77%) | |
| IV | 2 (50%) | 2 (50%) | |
| . | Dead 3–12 months (N = 36) . | Survived >1 year (N = 202) . | P-value . |
|---|---|---|---|
| Median age [in years, (IQR)] | 62 (57–69) | 62 (55–68) | 0.659 |
| Performance status | |||
| 0 | 18 (11%) | 147 (89%) | 0.006 |
| 1, 2 | 18 (25%) | 55 (75%) | |
| Tumour differentiation | |||
| Low to moderate | 9 (8%) | 111 (92%) | 0.001 |
| Poor/high grade | 27 (23%) | 91 (77%) | |
| Clinical T classification | |||
| Tx, T1 or T2 | 3 (8%) | 36 (92%) | 0.142 |
| T3 or T4 | 33 (17%) | 161 (83%) | |
| Induction | |||
| Chemo | 34 (18%) | 154 (82%) | 0.013 |
| Chemo-RT | 2 (4%) | 48 (96%) | |
| Clinical response | |||
| Minimal/stable/progression | 12 (24%) | 38 (76%) | 0.012 |
| Partial/complete | 11 (9%) | 106 (91%) | |
| Missing or no data | N = 13 | N = 58 | |
| ‘R’ status | |||
| R0 | 30 (13%) | 193 (87%) | 0.014 |
| R1 | 6 (40%) | 9 (60%) | |
| Path stage | |||
| 0 (CPR) | 0 (0%) | 28 (100%) | 0.001 |
| I | 2 (7%) | 26 (93%) | |
| II | 5 (8%) | 56 (92%) | |
| III | 27 (23%) | 90 (77%) | |
| IV | 2 (50%) | 2 (50%) | |
Comparison of patients who died within 1 year versus those surviving greater than 1 year
| . | Dead 3–12 months (N = 36) . | Survived >1 year (N = 202) . | P-value . |
|---|---|---|---|
| Median age [in years, (IQR)] | 62 (57–69) | 62 (55–68) | 0.659 |
| Performance status | |||
| 0 | 18 (11%) | 147 (89%) | 0.006 |
| 1, 2 | 18 (25%) | 55 (75%) | |
| Tumour differentiation | |||
| Low to moderate | 9 (8%) | 111 (92%) | 0.001 |
| Poor/high grade | 27 (23%) | 91 (77%) | |
| Clinical T classification | |||
| Tx, T1 or T2 | 3 (8%) | 36 (92%) | 0.142 |
| T3 or T4 | 33 (17%) | 161 (83%) | |
| Induction | |||
| Chemo | 34 (18%) | 154 (82%) | 0.013 |
| Chemo-RT | 2 (4%) | 48 (96%) | |
| Clinical response | |||
| Minimal/stable/progression | 12 (24%) | 38 (76%) | 0.012 |
| Partial/complete | 11 (9%) | 106 (91%) | |
| Missing or no data | N = 13 | N = 58 | |
| ‘R’ status | |||
| R0 | 30 (13%) | 193 (87%) | 0.014 |
| R1 | 6 (40%) | 9 (60%) | |
| Path stage | |||
| 0 (CPR) | 0 (0%) | 28 (100%) | 0.001 |
| I | 2 (7%) | 26 (93%) | |
| II | 5 (8%) | 56 (92%) | |
| III | 27 (23%) | 90 (77%) | |
| IV | 2 (50%) | 2 (50%) | |
| . | Dead 3–12 months (N = 36) . | Survived >1 year (N = 202) . | P-value . |
|---|---|---|---|
| Median age [in years, (IQR)] | 62 (57–69) | 62 (55–68) | 0.659 |
| Performance status | |||
| 0 | 18 (11%) | 147 (89%) | 0.006 |
| 1, 2 | 18 (25%) | 55 (75%) | |
| Tumour differentiation | |||
| Low to moderate | 9 (8%) | 111 (92%) | 0.001 |
| Poor/high grade | 27 (23%) | 91 (77%) | |
| Clinical T classification | |||
| Tx, T1 or T2 | 3 (8%) | 36 (92%) | 0.142 |
| T3 or T4 | 33 (17%) | 161 (83%) | |
| Induction | |||
| Chemo | 34 (18%) | 154 (82%) | 0.013 |
| Chemo-RT | 2 (4%) | 48 (96%) | |
| Clinical response | |||
| Minimal/stable/progression | 12 (24%) | 38 (76%) | 0.012 |
| Partial/complete | 11 (9%) | 106 (91%) | |
| Missing or no data | N = 13 | N = 58 | |
| ‘R’ status | |||
| R0 | 30 (13%) | 193 (87%) | 0.014 |
| R1 | 6 (40%) | 9 (60%) | |
| Path stage | |||
| 0 (CPR) | 0 (0%) | 28 (100%) | 0.001 |
| I | 2 (7%) | 26 (93%) | |
| II | 5 (8%) | 56 (92%) | |
| III | 27 (23%) | 90 (77%) | |
| IV | 2 (50%) | 2 (50%) | |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
